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Introduction
The publication of the second edition of the 
"Recommendations for the prevention and treatment 
of haemolytic disease of the foetus and newborn" is 
the result of collaboration between the Italian Society 
of Transfusion Medicine and Immunohaematology 
(SIMTI, Società Italiana di Medicina Trasfusionale 
e Immunoematologia) and the Italian Society of 
Gynaecology and Obstetrics (SIGO, Società Italiana 
di Ginecologia e Ostetricia).
The recommendations published in 20061 have been 
revised in the light of current scientific evidence: the 
immunohaematological and instrumental investigations 
that should be performed in the antenatal and perinatal 
periods, the immunoprophylaxis (IP) to prevent the 
haemolytic disease of the foetus and newborn (HDFN 
due to RhD incompatibility and the treatment to use if 
HDFN develops are described.
The recommendations are focused on the prevention and 
management of HDFN, in particular that one due to RhD 
incompatibility, the most serious form of this condition. 
Although IP has dramatically reduced the number of cases of 
HDFN, this disease continues to occur and engage specialists 
in Transfusion Medicine, Obstetrics and Neonatology. The 
recommendations are aimed at Transfusion Structures 
(TS) and all public facilities pertaining to Mother and 
Child Departments, Family Planning Clinics and private 
structures managing pregnancies, including those in which 
the woman gives birth at home. The prevention of HDFN 
must be guaranteed, through organisational models adapted 
to local circumstances, to all pregnant women for whom it 
is deemed necessary and the women must also be ensured 
adequate information.
Besides HDFN due to RhD incompatibility, the 
recommendations also cover less frequent forms of the 
disease, caused by immunisation to other blood group 
antigens, and by ABO incompatibility, which is a more 
frequent laboratory finding, although of less importance 
from a clinical point of view.
These recommendations will be periodically 
reviewed in the light of evolving scientific knowledge, 
technology and clinical practice. They were developed 
on the basis of an analysis of current scientific 
literature (identified through bibliographic searches of 
Medline/PubMed and Ovid databases) and were 
submitted to the consensus of experts from SIMTI 
and SIGO. Protocols jointly agreed upon by the 
Transfusion Medicine and Immunohaematology Services 
(SIMT, Servizio di Immunoematologia e Medicina 
Trasfusionale) and Obstetricians-Gynaecologists working 
in the same territory, including at a regional level, should be 
drawn up to promote compliance among pregnant women.
Purpose of the recommendations
The purpose of this document is to give correct 
guidance on the management and prevention of HDFN 
with the aim of promoting homogeneous practices 
throughout Italy, ensuring a minimum common 
denominator of quality that can be achieved in all health 
care structures2 used by pregnant women or females of 
childbearing potential*.
The dual value of these recommendations is 
that besides being a technical and scientific support 
for doctors making clinical decisions regarding the 
management of HDFN, they also provide updates on 
the risks associated with immunisation in females of 
childbearing potential.
The recommendations are not intended in any way 
to replace either the physician's clinical evaluation of 
individual cases or the doctor's personal experience; 
they are, rather, a reference tool that can also be used 
to check the correctness of treatment. The final decision 
on a given treatment must always be taken by the 
doctor in the light of the clinical picture and resources 
available; however, substantial deviations from these 
recommendations should be documented and justified 
in the patient's clinical records. For this purpose specific 
indicators for monitoring and evaluation have been 
identified to use in clinical audits.
* The term "females of childbearing potential" means patients (from the age of 4-6 
months until menopause) who could be or become pregnant and, therefore, be at 
risk of HDFN.
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Expected benefits
The expected benefits of the dissemination of these 
recommendations for the prevention and management 
of HDFN are as follows:
- a decrease in the incidence of HDFN;
- a decrease in the incidence of alloimmunisation;
- an increase in appropriate clinical use of blood 
components in the foetal and neonatal periods;
- an increase in the appropriate clinical use of blood 
components in females of childbearing potential;
- an increase in the appropriate clinical use and dosages 
of anti-D immunoglobulin (Ig);
- greater involvement of patients in decisions related 
to the prevention and management of HDFN.
Intended users of the recommendations
Doctors and healthcare workers involved in the 
prevention, diagnosis and treatment of HDFN.
Applicability
These recommendations are applicable to females of 
childbearing potential, pregnant women at risk of HDFN 
and foetuses/neonates affected by haemolytic disease 
caused by materno-foetal alloimmunisation.
Methodology of the Working Group and grades 
of recommendation
The process of developing these recommendations, 
in accordance with the indications contained in the 
methodology manual of the National Guidelines 
Programme3, was based on systematic reviews 
of the literature and updating of already existing 
recommendations on the subject. For most of the 
recommendations there is an explicit evaluation of the 
quality of the proof leading to the recommendation and 
the strength with which the recommendation is made. 
In the absence of clear proof, the recommendations are 
based on a consensus of published opinions of experts 
and that of the Working Group.
The methodology used to derive the grades of 
recommendation was based on that used by the Grading 
of Recommendations Assessment, Development and 
Evaluation (GRADE) Working Group4-6. According to 
the GRADE system, recommendations are classified by 
grades, expressed in Arabic numbers (1, 2), depending 
on their strength, and by letters (A, B, C) depending on 
the quality and type of evidence provided by the studies 
on which the recommendations are based.
In detail:
- Grade 1: the authors are confident that the benefits 
for health clearly outweigh the undesirable effects, 
in terms of both risk and economic cost. This is, 
therefore, a strong recommendation.
- Grade 2: the authors are less certain and the difference 
between desirable and undesirable effects is less 
clear. This is, therefore, a weak recommendation.
As to the quality and type of evidence provided by 
the studies in support of the recommendations, there are 
three levels of classification:
- Grade A: high level of evidence. 
 The evidence derives from the analysis of numerous, 
substantial randomised studies without major 
limitations. It is unlikely that further research would 
alter the conclusions reached by these studies.
- Grade B: moderate level of evidence. 
 The evidence is derived from randomised clinical 
trials but with important limitations (for example, 
inconsistent results, wide confidence intervals, 
methodological problems). Grade B is also attributed 
to recommendations derived from strong evidence 
collected in observational studies or case series (for 
example, treatment effects or the demonstration of a 
dose-response effect). Further research could change 
the conclusions of these studies.
- Grade C: low or very low level of evidence. 
 The evidence is derived from an analysis of 
observational clinical studies with less consistent 
results or from the clinical experience/opinions of 
experts. Further research is required to consolidate 
or change the conclusions presented.
Generally speaking, it can be assumed that for all 
recommendations other than Grade 1A the authors 
recognise that other interpretations of the available 
evidence and other "clinical policies" are reasonable.
The conventional classification of evidence is 
based on mathematical and statistical criteria, with 
the "strength" of the evidence being assigned, in 
order, to: meta-analyses, randomised controlled 
trials, retrospective analyses, prospective follow-ups, 
cross-sectional population studies, reviews, anecdotal 
reports. This is correct as far as regards strictly clinical 
studies, especially if they are investigations of therapies 
and focused on objective evaluations of outcome.
Nevertheless, the recommendations in some fields 
are weak; in contrast, in other areas the availability of 
clinical studies carried out with rigorous methodology 
in large groups of subjects has enabled specific 
recommendations to be made with more confidence.
It was not always possible to use aggregate data from 
meta-analyses: these variables increase the margins for 
individual decisions by each doctor and for each patient.
As to transfusion support for HDFN in the 
antenatal and postnatal periods (intrauterine 
transfusion, exchange transfusion [ET], neonatal 
transfusion), the fundamental principles taken from 
the "Recommendations for transfusion therapy in 
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neonatology"7 and subsequent amendments are reported 
in the appendix.
The appendix also contains some recommendations 
to be followed in order  to avoid the risk of immunisation 
when transfusing females of childbearing potential, 
a summary of the investigations to carry out during 
pregnancy and the puerperium to enable the correct 
prevention of HDFN, and a flow-chart describing the 
immunohaematological monitoring of women during 
pregnancy and at delivery. Finally, the recommendations 
are summarised and reported with their classification at 
the end of the appendix.
Each member of the Working Group has signed a 
statement, which conforms with the one adopted by the 
National Guidelines Programme, declaring that they 
have no conflicts of interest3.
Haemolytic disease of the foetus and newborn 
due to maternal-foetal RhD incompatibility
The anti-D alloantibody is the antibody most 
frequently responsible for HDFN8,9. Before the 
introduction of anti-D IP, HDFN secondary to anti-D 
immunisation affected 1% of neonates and was the cause 
of death of one in every 2,200 babies born10. Although 
the introduction of post-partum IP in RhD negative 
pregnant women drastically reduced the incidence of 
cases of HDFN11, HDFN due to anti-D continues to 
occur in 0.4 of every 1,000 births12-13 and red blood cell 
alloimmunisation still remains the most common cause 
of foetal anaemia14. There are various reasons for the 
continued occurrence of this disease: (i) the possible 
development of anti-D immunisation during a pregnancy 
as a result of an occult foetal-maternal haemorrhage 
(FMH), usually after the 28th week of gestation, which 
affects about 1% of RhD negative mothers of a RhD 
positive foetus15; (ii) lack of administration of IP; (iii) 
ineffective IP because the amount administered was not 
sufficient for the volume of the FMH; (iv) possible errors 
in the typing of the pregnant woman, puerpera or neonate; 
and (v) possible errors in the transfusion treatment of 
females of childbearing potential (transfusion of red 
blood cell concentrates with mismatched RhD antigen).
The fundamental cause of HDFN is the reaction 
between class IgG maternal antibodies and antigens on 
foetal red blood cells, leading to the destruction of these 
cells, mainly in the spleen.
HDFN rarely occurs during a first pregnancy, 
unless the mother has been previously sensitised 
by transfusions. Usually, during the first pregnancy 
primary immunisation takes place; this immunisation 
is characterised by the production of a small amount 
of IgM antibodies, immunoglobulins which do not 
cross the placenta. In subsequent pregnancies, and 
after further exposure to the antigen, as a result of 
the secondary immunisation, IgG antibodies, which 
can cross the placenta and cause haemolysis, are 
produced. The immune response depends on the entity 
of the FMH, the number of immunising events and the 
capacity of the woman's response. ABO incompatibility 
between mother and foetus partially protects against 
immunisation.
In the natural history of HDFN, without any kind of 
intervention, in 50% of cases the foetus has only mild 
signs of the disease and recovers without any treatment; 
in 25% of cases the foetus develops haemolysis and 
kernicterus, if not treated adequately at birth; and in the 
remaining 20-25% of cases, HDFN due to anti-D may 
present in its most severe form (hydrops foetalis and 
death) before the 34th week of gestation16.
However, with the improvement of maternal and 
foetal monitoring and the current possibility of in utero 
treatment, the incidence of severe cases (hydrops and 
death) has now been reduced to about 10%17.
Haemolytic disease of the foetus and newborn 
due to incompatibility for other red blood cell 
antigens
Besides the RhD antigen, other antigens belonging 
to the Rh system and other known blood group systems 
(with the possible exclusion of those of the Lewis, Chido 
and Rodgers, and Knops systems and of the I/i collection) 
can also induce the production of IgG antibodies and, 
therefore, provoke HDFN if a person lacking an antigen 
comes into contact with that antigen as a result of a 
pregnancy or transfusion. As a general rule, the forms 
of HDFN not due to RhD incompatibility are clinically 
benign, such that only 10% of them are clinically severe 
enough to require transfusion therapy; nevertheless, there 
are descriptions of fatal cases in the literature18.
The order of frequency of HDFN, after the forms 
due to RhD incompatibility and ABO incompatibility, 
are those caused by incompatibility for the c antigen (r'), 
the Kell antigen (K1), the C antigen and the antigens of 
the Duffy system19-20. Still in strict order of frequency, 
there are the forms of HDFN due to incompatibility 
for antigens of the Kidd, MNS, and Dombrock systems 
and others, which are all very rare. Anti-Cw, -Fyb, -Jka, 
-Jkb, -Jk3, -S, and -s usually only cause a positive direct 
antiglobulin test (DAT) in the neonate and treatment, if 
necessary is almost always limited to phototherapy21.
Anti-M, which may also be of the IgG class, rarely 
cause HDFN. The same applies for warm autoantibodies. 
Antibodies such as anti-I, -P, -Lea and -Leb can be 
ignored because the corresponding antigens are scarcely 
present at birth.
Various studies22-25 have shown that HDFN caused 
by anti-K differs from that due to anti-D in a number of 
ways. In women with anti-K, the obstetric history is not 
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usually predictive of the severity of the disease; there is 
only a weak correlation between antibody titre and the 
severity of the disease, haemolysis and the consequent 
hyperbilirubinaemia are not dominant features of the 
disease and the suppression of foetal erythropoiesis, 
rather than haemolysis, is the most important pathogenic 
mechanism in causing foetal anaemia. Pregnancies in 
which anti-K maternal-foetal alloimmunisation has 
occurred, even when the antibody titre is low (1:8 or 
greater), must, therefore, be considered at risk, given 
the severity of the foetal and/or neonatal clinical 
manifestations.
The recent increase in migration to Italy has led to 
the diagnosis of other forms of HDFN due to antigens 
rarely observed in the Italian population. The search for 
irregular antibodies in these forms of HDFN is often 
falsely negative because of the lack of the relevant 
antigens in the test red cell panels commonly used, which 
are prepared with red blood cells from Caucasians. In 
these cases, the alloantibody involved can be detected 
and identified by using the father's red cells (if ABO 
compatible with the mother' ones), or, after delivery, the 
neonate's cells. The protocols regarding investigations 
to carry out during pregnancy and in the perinatal and 
postnatal periods, as well as the treatment, are not 
different from those recommended for HDFN due to 
RhD incompatibility, to which the reader is referred.
Once an antibody specificity has been identified, the 
test red cells to use in controls, in determining the titre 
and in studies of the eluate of neonatal erythrocytes must 
express the antigen in question. In contrast, the red cells 
to use for a possible ET or for transfusion into the neonate 
must not carry the antigen involved.
Haemolytic disease of the foetus and newborn 
due to maternal-foetal ABO incompatibility
HDFN due to ABO incompatibility is currently the 
most common neonatal haemolytic disease in the western 
world; indeed, in 15-20% of pregnancies in the white 
population there is incompatibility between a group 
O mother and a group A or B child; in 10% of these 
pregnancies, HDFN develops as a result of destruction 
of the foetal red blood cells, caused by IgG class anti-A 
and/or anti-B antibodies in the maternal serum. The 
mother-child serological combination in which a clinically 
relevant ABO HDFN develops most readily is a group O 
mother and a group A neonate.
However, only in about 1.5-2% of cases does the 
haemolytic disease require transfusion support26,27. There 
are various reasons for the prevailing modest clinical 
expression of HDFN due to ABO incompatibility:
- the expression of A and B antigens on foetal and 
neonatal red blood cells is low;
- the A and B substances, ubiquitously present on 
endothelial and epithelial cells, including placental 
ones, adsorb some of the maternal IgG that crosses 
the placenta;
- anti-A and anti-B IgG are predominantly IgG2, a 
subclass of Ig with a lesser capacity to cross the 
placental barrier actively.
Nevertheless, there are occasional reports in the 
literature of severe cases of haemolytic disease that have 
required ET and complex management28,29.
The incidence of HDFN due to ABO incompatibility is 
higher in African and Arab populations because of the more 
frequent expression of A and B genes in these populations. 
Given the migratory phenomena involving Italy (the 2013 
CEDAP report [analysis of Birth Support Certificates] 
described that, in 2010, 18.3% of births were to women 
of non-Italian citizenship, with the peak being 28% in the 
region of Emilia Romagna), it can be predicted that the 
incidence of this type of HDFN will increase in the future30.
The incidence of HDFN due to ABO incompatibility 
is the same in first pregnancies as it is in subsequent 
pregnancies; the disease is, therefore, neither preventable 
nor predictable.
The search for anti-A and/or anti-B IgG during a 
pregnancy is of little use for predicting the development 
of ABO HDFN in the unborn child. In fact, most pregnant 
women, especially those with group O blood, have anti-A 
and/or anti-B (and anti-A,B) IgG in their serum, whereas 
relatively few neonates are affected by haemolytic disease, 
particularly clinically important forms.
Investigations during pregnancy to prevent and 
manage haemolytic disease of the foetus and 
newborn
Immunohaematological tests to perform in all women
(Table I)
- ABO blood group and RhD factor must be determined 
in all pregnant women, preferably within the first 
trimester of pregnancy. The tests must be performed 
in a TS using validated methods9,31-32.
- Samples of blood from pregnant women must carry the 
surname, name and date of birth of the patient and the 
signature of the person who took the sample33,34. The 
patient's personal data must be transcribed in the presence 
of the patient herself, who must confirm the data.
- Two different monoclonal anti-D reagents, which must 
not recognise the DVI variant of the RhD antigen, must 
be used to determine the RhD type32,33. Determination 
of weak D antigen is not recommended since this is not 
useful and could lead to a dangerous omission of IP in 
the absence of in depth investigations, which cannot 
be carried out in all immunohaematology laboratories.
- All pregnant RhD negative women should be given 
an appropriate certificate stating their RhD group 
and the indication for IP with anti-D Ig.
- At the same time as typing a woman's blood group 
in the first trimester, a search for irregular antibodies 
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to red blood cells must be carried out in the 
 plasma/serum of the pregnant woman using an 
indirect antiglobulin test (IAT), with a validated 
method, capable of picking up all clinically 
significant antibodies.
- The requests accompanying the samples must carry 
information on the state of the pregnancy and any 
anti-D IP performed in the preceding 6 months.
- It is suggested that an anti-IgG antiserum antiglobulin 
is used for the IAT. A "broad spectrum" antiserum 
antiglobulin is acceptable provided that, if the result 
is positive, the test is repeated only with anti-IgG 
antiserum antiglobulin or with methods suitable for 
revealing the clinical significance of the antibody 
detected.
- W h e n  a n t i b o d i e s  a r e  d e t e c t e d ,  t h e 
immunohaematological report must contain 
information on the clinical relevance of the result 
and whether further investigations are necessary.
- The red blood cell panels used for antibody screening 
and detection must conform with the indications of 
the SIMTI Standards33, although it is not considered 
necessary to test red blood cells that express low 
frequency antigens such as Cw, Kpa and Lua35. The 
routine use of techniques involving enzyme-treated 
red blood cells is not advised36,37, since they could 
show antibodies of no significance for HDFN (cold 
autoantibodies, anti-Lewis, anti-P, etc.).
- If the search for antibodies is positive, in order to 
evaluate the risk of HDFN, the specificity, titre and 
origin of the antibodies must be determined, with a 
careful immunohaematological and obstetric history 
from the woman. In this phase it can also be useful to 
determine the IgG subclasses present to assess the real 
risk of haemolysis as precisely as possible.
- The search for and monitoring of anti-A and anti-B 
immune antibodies in pregnant women are not 
recommended, because their presence does not 
predict the development of ABO HDFN and does 
not cause problems to the foetus in utero38.
- At 28 weeks of gestation, the IAT must be repeated 
in all women29,39, regardless of their RhD status. If no 
further blood group typing results are available in the 
archives of the TS in addition to the one performed 
during the first trimester, it is suggested that, besides 
the IAT, ABO and RhD groups are checked again37.
- In RhD negative women who undergo antenatal 
prophylaxis at 28 weeks of gestation, the IAT must 
be performed before the IP is administered.
- Searches for other antibodies should not be carried out 
routinely if the result of the IAT at 28 weeks of gestation 
is negative. Irregular antibodies detected only in the third 
trimester of pregnancy do not usually cause HDFN40,41.
- In women with antibodies that are not clinically 
significant, it is recommended that red blood cell 
antibodies are identified again at 24 and 34 weeks 
of gestation, if the woman is RhD negative, and at 34 
weeks of gestation, if the woman is RhD positive29.
Table I -  Recommendations on immunohaematological tests 
to perform in all women.
Rec. n. Recommendation GoR
1
It is recommended that the ABO group and RhD 
factor are determined and a search for irregular 
antibodies is carried out with an IAT in all pregnant 
women, independently of their RhD status, within 




I t  i s  s u g g e s t e d  t h a t  t h e  s a m p l e s  f o r 
immunohaematological investigations are identified 
as samples for pre-transfusion tests and carry the 
surname, name and date of birth of the patient and 
the signature of the person who took the sample.
2C
3
It is suggested that all pregnant women are notified 
of their RhD status because of the possible need for 
prophylaxis with anti-D Ig.
2B
4
It is suggested that the search for irregular antibodies 
is repeated in all pregnant women at 28 weeks of 
gestation, regardless of their RhD status. In RhD 
negative women receiving antenatal prophylaxis at 
28 weeks of gestation, the IAT should be performed 
before the IP is administered.
2B
5
If the search for antibodies is positive, for the 
purpose of evaluating the risk of HDFN, it is 
suggested that the specificity, titre and origin of 
the antibodies are determined and that a careful 




It is suggested that RhD typing and screening and 
identification of irregular antibodies is performed 




It is recommended that anti-A and anti-B immune 
antibodies are not searched for or monitored in 
pregnant women.
2B
Immunohaematological investigations to perform in 
the case of positive antibodies (Table II)
- In the presence of clinically significant antibodies, 
the pregnancy should be followed in a centre 
with monitoring protocols jointly agreed by 
immunohaematologists and obstetricians.
- Following the identification of an antibody that is 
clinically significant with regards to HDFN, the 
next step is to establish whether the father of the 
unborn baby has the corresponding antigen and 
whether he is a heterozygote or homozygote42,43. 
Therefore, if the couple agrees, it is suggested that 
114
Bennardello F et al
Blood Transfus 2015; 13: 109-34  DOI 10.2450/2014.0119-14
the partner's ABO and RhD groups are determined 
and that he is phenotyped for Rh and other red blood 
cell antigens, in the event that there are clinically 
significant alloantibodies to these antigens. If the 
father is a homozygote for the corresponding antigen 
and paternity is certain, the foetus is definitely at risk 
of HDFN.
-  In the past, serological tests were used for the study 
of paternal zygosity, but once the Rh phenotype was 
determined, heterozygosity of the RhD antigen could 
only be evaluated through the analysis of tables of 
frequency, with often inaccurate results. More recently 
polymerase chain reaction (PCR) techniques have been 
developed for the determination of RhD zygosity44.
- PCR methods are not necessary to determine paternal 
zygosity for the other antigens that are always 
expressed (systems with co-dominant alleles) and 
in these cases serological methods can be used to 
determine the paternal genotype.
- If the father is heterozygous for the antigen 
against which the identified antibody is targeted 
and the woman is undergoing invasive antenatal 
diagnosis for other indications, it is suggested that 
the genotype of the foetus is determined by PCR 
analysis carried out on samples of foetal material 
collected by amniocentesis, from chorionic villi or 
by cordocentesis45. Unfortunately, however, these 
invasive techniques increase the risk of spontaneous 
abortion and can raise the levels of antibodies and 
should not, therefore, be used unless there are other 
reasons for performing them.
- The foetal RhD genotype can also be determined 
directly on samples of maternal plasma between 
the end of the first and the beginning of the second 
trimester of pregnancy46. Genomic identification of 
the RhD characteristics of the foetus is, currently, 
the standard of management in women with anti-D 
alloimmunisation in many European countries. 
However, it is not free of drawbacks and/or errors, 
and must be carried out in centres that have 
validated the procedures. The reported sensitivity 
and specificity of these PCR DNA tests are 98.7 and 
100%, respectively, with a low percentage of false 
negatives (1-3%)47,48.
- DNA probes for the RhD gene are currently available 
in Italy, but some experience is also reported with 
probes for the genes of the following antigens: c, e, 
C, E, K, k, Fya, Fyb, Jka, Jkb, M, S, s49,50.
- In RhD negative women anti-D Ig administered 
passively after potentially immunising events or at 
28 weeks of gestation for antenatal prophylaxis are 
detectable in the circulation for at least 3 months, 
depending on the dose administered and the 
sensitivity of the test. The anti-D Ig administered 
for IP cannot be differentiated from the low levels 
of active natural immune anti-D Ig51, but the levels 
of anti-D Ig introduced with IP decrease, whereas 
the levels of natural immune anti-D remain stable 
or increase if the antigenic stimulus persists.
-  If no IP has been given or there is no information on 
IP, the anti-D found must be carefully monitored. If 
the anti-D titre tends to decrease, undocumented IP 
should be suspected, whereas if the titres are stable 
or increase, immune anti-D must be suspected.
Table II - Recommendations on immunohaematological 
investigations to perform in the case of positive 
antibodies.
Rec. n. Recommendation GoR
8
If a woman has alloantibodies against clinically 
significant antigens for HDFN, it is suggested that, if 
the couple agrees, the red cell antigens against which 
the antibodies are targeted are determined in the 
woman's partner, in order to assess the risk of HDFN.
2C
9
In a woman undergoing invasive antenatal diagnosis 
for other reasons, it is suggested that the foetal 
genotype is determined by PCR analysis of a sample 
of foetal material obtained by amniocentesis, from 
chorionic villi or by cordocentesis if the father 
is heterozygous for the antigen against which the 
identified antibody is targeted. The foetal RhD 
genotype can also be determined directly on a 
sample of maternal plasma between the end of the 
first trimester of pregnancy and the beginning of 
the second.
2C
Antibody titration (Table III)
Titration is the simplest and most commonly 
used laboratory method to evaluate the strength of 
an antibody. Titration of anti-D or other antibodies 
that are clinically significant for HDFN helps the 
clinician to make decisions, for example, on when to 
start monitoring a foetus with the techniques available. 
The anti-D titre is not, however, strictly related to the 
onset of HDFN; fast increases in the antibody titre are 
more significant.
- Once an antibody has been identified and recognised 
as a potential cause of HDFN, its titre must be 
determined using a standardised technique.
- If a pregnant woman has anti-D antibodies, or 
other antibodies that are clinically significant 
with regards to HDFN, the antibody titre must be 
determined every 4 weeks until the 18th week of 
gestation and then every 2 to 4 weeks, depending 
on the clinical relevance and the values found. A 
fast increase in the titre necessitates more frequent 
immunohaematological monitoring and closer 
maternal-foetal surveillance.
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- It is suggested that D-heterozygous (R1r, R2r) red 
blood cells are used for the anti-D titration, since 
these have the same antigenic profile as that of the 
red blood cells from a heterozygous foetus52,53; it is, 
however, recommended that test red blood cells of the 
same D zygosity are always used in the comparative 
titrations performed in the following weeks.
- The critical value of the antibody titre is that 
associated with a significant risk of hydrops foetalis. 
For anti-D antibody, if the titration is performed with 
an IAT in physiological saline (without additives), 
with an incubation of 60 minutes at 37 °C (standard 
technique), using anti-IgG, the critical titre is 1:32.
- If other techniques are used, each laboratory must 
validate the methods involved and establish the 
critical value for each method adopted.
- The titration must be performed on samples of serum 
or plasma and in subsequent controls the same type of 
biological material must be used: the results should 
always be compared with those of the previously 
tested samples (kept frozen), using the same test red 
blood cells with the same antigen expression in order 
to determine correctly any changes in antibody titre 
occurring during pregnancy.
- To ensure that results from different laboratories 
can be compared, each laboratory must indicate on 
its report the method used for the titration and the 
specific critical level.
Table III - Recommendations on antibody titration.
Rec. n. Recommendation GoR
10
In order to perform anti-D titration, it is suggested 
that D-heterozygous (R1r, R2r) red blood cells are 
used, because these are best able to demonstrate 
foetal antigen expression. In any case, the same test 
red blood cells with the same zygosity must always 




If a pregnant woman has anti-D antibodies, or other 
antibodies that are clinically significant with regards 
to HDFN, it is suggested that the antibody titre 
is measured every 4 weeks until the 18th week of 
gestation and then every 2-4 weeks. The results of 
the titration must be compared with those obtained 
in the previously tested samples, using test red blood 
cells with the same antigen expression.
2C
Instrumental investigations and foetal monitoring 
(Table IV)
- If the immunohaematology laboratory reports that 
a specific critical level has been reached or that 
there is a rapid increase in the antibody titre, close 
monitoring of HDFN must be established with 
 non-invasive methods, such as ultrasonography 
 and/or Doppler velocimetry.
- The test of choice for evaluating the degree of 
foetal anaemia, before the manifestations of 
hydrops foetalis, is the determination of the peak 
systolic flow velocity in the middle cerebral artery 
 (MCA-PSV) with Doppler ultrasound54-56. This 
technique is now recognised as the most effective for 
non-invasively identifying moderate-severe anaemia 
and has definitively replaced spectrophotometric 
analysis of the amniotic fluid, used in the past to 
determine bilirubin levels57,58.
The methods of maternal-foetal monitoring, used 
in different periods of a pregnancy, are indicated 
below10,54,59.
- Before 18 weeks of gestation: ultrasound dating of 
the pregnancy and ultrasonographic evaluation of 
the presence/absence of ascites/hydrops foetalis and 
foetal heart beat every 4 weeks.
- Between 18+0 and 25+6 weeks of gestation: ultrasound 
and Doppler-velocimetric evaluation of indirect signs 
of foetal anaemia at intervals of 1-3 weeks, depending 
on the severity of the case. Basically, two parameters 
are evaluated: presence/absence of ascites/hydrops 
foetalis and the MCA-PSV. If the values of this latter 
are found, and confirmed, to be more than 1.5 times 
higher than the median value for gestational age, the 
foetal blood count is evaluated by cordocentesis.
- Between 26+0 and 34+6 weeks of gestation: ultrasound 
and Doppler-velocimetric evaluation of indirect signs 
of foetal anaemia every 1-2 weeks, depending on the 
severity of the case, using the above described criteria. 
If ultrasonographic signs of foetal anaemia are found, 
the foetal blood count is evaluated by cordocentesis.
- After 35+0 weeks of gestation:  ultrasound 
evaluation of indirect signs of foetal anaemia every 
 4-10 days, depending on the severity of the case, 
using the above described criteria. After 35 weeks 
of gestation, the reliability of the MCA-PSV test 
alone is limited; greater attention should, therefore, 
be given to any appearance of ascitic fluid levels, 
and cardiotocographic monitoring, which should 
be performed at least weekly. If one or more of the 
parameters are abnormal, the delivery should be 
induced, following prophylaxis against respiratory 
distress syndrome.
- If the parameters remain within the normal range, 
it is advisable that the delivery takes place between 
 38+0 and 38+6 weeks, in any case. The method of delivery 
must be chosen exclusively on the basis of obstetric 
considerations; the presence of alloimmunisation is 
not a contraindication to vaginal delivery.
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Table IV -  Recommendations on instrumental investigations 
and foetal monitoring.
Rec. n. Recommendation GoR
12
In the case of risk of HDFN, it is recommended that 
the foetus is monitored with non-invasive methods, 
such as ultrasonography and/or Doppler velocimetry. 
The parameters to evaluate are the presence/absence of 
ascites/hydrops foetalis and the MCA-PSV.
1B
Postnatal immunohaematological investigations
Tests to perform in all neonates (Table V)
- It is suggested that a DAT is performed on the cord 
blood of all neonates.
- The isolated presence of a positive DAT does not 
allow the diagnosis of HDFN to be made. However, 
in the presence of a positive DAT, the neonate's levels 
of haemoglobin and bilirubin must be monitored in 
order to diagnose or exclude HDFN.
- In the event that the DAT is positive and the neonate 
shows signs and symptoms of HDFN, the antibody 
must be eluted from cord red blood cells in order to 
confirm the antibody specificity. In suspected cases 
of HDFN, the cord blood red cells must be tested for 
the corresponding antigen.
- There are numerous elution methods: in the case of 
anti-D antibodies, it is recommended that a technique 
sufficiently specific for the elution of anti-Rh 
antibodies is used.
- If an anti-D is eluted, consideration should be 
given to whether the mother has previously been 
administered antenatal IP. It has been demonstrated 
that following systemic antenatal IP, the anti-D Ig 
can cross the placenta, reach the foetal circulation 
and bind to RhD positive foetal red blood cells. 
These anti-D do not cause the destruction of foetal 
or neonatal red cells60.
- In neonates of RhD negative mothers, the RhD 
phenotype should be determined on the same sample 
of cord blood with methods that can also demonstrate 
the weak D phenotype, and at least its most common 
variant, DVI 33.
Table V - Recommendations on tests to perform in all neonates.
Rec. n. Recommendation GoR
13
It is suggested that a DAT is carried out on a sample 
of cord blood of all neonates. In the event of a positive 
DAT and in the presence of clinical signs of HDFN, it is 
suggested that the antibody is eluted from the cord blood 
red cells, in order to confirm the antibody's specificity.
2C
14
In neonates of RhD negative mothers, it is suggested 
that the same sample of cord blood used for the 
DAT is used to determine the RhD phenotype, 
with methods capable of also detecting the weak D 
phenotype and at least its most common variant, DVI.
2C
Investigations to perform at birth in the case of 
suspected haemolytic disease of the foetus and 
newborn due to maternal-foetal ABO incompatibility
(Table VI)
- When the mother is group O and there is laboratory 
(DAT positive) or clinical (jaundice) evidence of 
neonatal haemolysis, in the absence of known causes, 
ABO/RhD blood group typing should be performed 
on cord blood cells and anti-A and/or anti-B IgG 
should be searched for in the maternal serum and 
titrated. The diagnosis of ABO haemolytic disease 
of the newborn is essentially clinical: in fact, very 
often, despite ABO incompatibility and anti-A and/or 
anti-B IgG in the mother's serum, the DAT is negative 
or inconclusive61,62.
- The search for and titration of IgG class immune 
anti-A or anti-B antibodies must be performed by 
an IAT after having cleaved the anti-A and/or anti-B 
isoagglutinins present in the maternal serum with 
reducing substances such as 2-mercaptoethanol 
(2-ME) or dithiothreitol (DTT), or using other 
commercially available neutralising substances.
- If the cord red blood cells are DAT positive, it is 
suggested that the IgG (anti-A and/or anti-B) attached 
to the neonatal erythrocytes are eluted. The best 
technique for eluting anti-A and anti-B IgG is rapid 
freeze-thawing, developed by Lui and described by 
Feng et al63; another method, which is quick and gives 
useful results, is heat elution64.
Table VI - Recommendations on investigations to 
perform at birth in the case of suspected 
haemolytic disease of the foetus and newborn 
due to maternal-foetal ABO incompatibility.
Rec. n. Recommendation GoR
15
In the presence of laboratory evidence (positive 
DAT) or clinical evidence (jaundice) of neonatal 
haemolysis, when the mother is group O, it is 
suggested that ABO/RhD blood group typing is 
performed on cord blood, anti-A and/or anti-B IgG 
are detected and titrated in the maternal serum and, 
in the event of a positive DAT, the IgG (anti-A 




A non-sensitised RhD negative woman who has not 
received IP has a 16% risk of becoming immunised in 
every pregnancy with a RhD positive neonate65. The 
most common immunising event is delivery, whether this 
is vaginal or by Caesarean section. However, potentially 
immunising events can also occur during pregnancy. 
Since IP has been introduced, HDFN secondary to 
anti-D immunisation has become a rare condition, with 
117
Blood Transfus 2015; 13: 109-34  DOI 10.2450/2014.0119-14
Recommendations for the prevention and treatment of HDFN
the percentage of successful postnatal IP having reached 
98-99%66,67.
Nevertheless, the risk of maternal immunisation in 
non-sensitised RhD negative women who undergo IP 
in the post-partum period and during pregnancy after 
potentially immunising events has not been completely 
eliminated. This is mainly because of unrecognised 
bleeding, which can occur during the third trimester 
of pregnancy and leads to silent immunisation68,69. The 
frequency of silent FMH increases with the progression 
of pregnancy and has been reported to reach 73% in the 
third trimester70,71. A systematic review of randomised 
controlled trials showed that routine, systematic 
antenatal prophylaxis in RhD negative pregnant women, 
administered in the third trimester of pregnancy, led to 
a further reduction of the risk of immunisation from 
1 to 0.2%72. Similar conclusions were drawn from a 
meta-analysis of non-randomised studies, in which it 
was estimated that there was an absolute reduction in 
risk from 0.9 to 0.3%73.
General indications (Table VII)
- IP with anti-D Ig must be given to all non-sensitised 
RhD negative women immediately after the delivery 
of a RhD positive neonate74,75, at 28 weeks of 
gestation and in the case of events that could cause 
immunisation76. The methods and doses to use are 
described in the following paragraphs.
- The TS that carries out the immunohaematological 
investigations aimed to prevent HDFN must indicate 
on the immunohaematological report form that IP 
should be performed, keep a register of RhD negative 
women to be given IP and, in close collaboration with 
the Obstetrics and Gynaecology units, monitor and 
record that the IP has been given31,33.
- If IP has been given during a pregnancy, the possible 
presence of passively introduced anti-D Ig should 
be considered in subsequent serological tests; 
this Ig must be distinguished from active anti-D 
alloimmunisation. The TS must, therefore, always be 
informed of the administration of anti-D Ig and, in 
most cases, documentation of the administration of 
anti-D Ig will enable active and passive immunisation 
to be differentiated.
- Before administering anti-D Ig, the woman's 
informed consent must be obtained, recorded and 
archived, as required by law34. The woman must be 
informed that the procedure is not without risks and 
must give her consent or refusal to the procedure in 
writing. An informed consent form is presented in 
the appendix.
- Antenatal IP with anti-D Ig is not indicated in a 
RhD negative woman with a RhD negative partner, 
provided that the paternity has been ensured by 
private interview with the woman.
- If there is a serological discrepancy in the 
determination of RhD, in accordance with the SIMTI 
Standards33, it is desirable that a partial D phenotype 
assigned by serological methods is confirmed by 
molecular biology techniques. In the event that it 
is not possible to identify the antigenic variant with 
molecular analysis of the RhD gene, the woman must 
be considered as RhD negative and given IP.
- In the light of current scientific knowledge, in cases in 
which molecular analysis can define the RhD antigen 
variant, IP with anti-D Ig is not indicated for weak D 
variants, type 1, 2, and 3. IP is necessary for all the 
other antigenic variants77-79.
- Mistaken administration of anti-D Ig to RhD positive 
women does not cause appreciable adverse effects in 
any case.
- In the event of apparent anti-D+C specificity, the 
presence of anti-G must be carefully evaluated. In 
these cases it is important to distinguish anti-D+C 
antibodies from anti-G antibodies because pregnant 
women with anti-G but without anti-D can benefit 
from IP with anti-D Ig in the antenatal and postnatal 
periods, which would not be necessary if anti-D 
antibodies were actually present. In the above 
described cases, mistaken attribution of an anti-D 
specificity could lead to IP not being given to women 
at risk80-82. In this situation, samples should be sent to 
a reference laboratory to determine the real specificity 
of the antibodies present83.
- The efficacy of the IP must be checked with a search 
for anti-D antibodies in the serum of the mother at 
least 6 months after delivery (to avoid interference by 
the anti-D introduced passively). A negative search 
for anti-D antibodies is evidence that the IP has been 
successful.
Table VII - Recommendations on anti-D immunoprophylaxis.
Rec. n. Recommendation GoR
16
It is suggested that IP is performed with anti-D Ig in 
women with a D variant phenotype poorly defined 
from a molecular point of view.
2C
17 Before administering anti-D Ig it is recommended that informed consent is obtained from the woman 1B
18
It is suggested that IP is not performed (since it 
is not indicated) with anti-D Ig in a RhD negative 
women with a RhD negative partner, provided that 




It is suggested that the efficacy of the IP is checked 
by a search for anti-D antibodies in the maternal 
serum at least 6 months after the delivery. The 
absence of anti-D antibodies at this point is evidence 
of the success of the IP.
2C
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Immunoprophylaxis  fol lowing potential ly 
immunising events during pregnancy (Table VIII)
- Prophylaxis with anti-D Ig is recommended in 
 non-immunised RhD negative women in the 
following circumstances that can promote the 
passage of foetal red blood cells into the maternal 
circulation21,75,84-89:
• invasive antenatal diagnosis: amniocentesis, 
cordocentesis, chorionic villus biopsy;
• dilation and curettage, elimination of one or more 
embryos, treatment to the foetus (introduction of 
shunts, intrauterine transfusion);
• direct, indirect, open or closed abdominal trauma;
• external cephalic version;
• antenatal haemorrhage;
• intrauterine foetal death;
• therapeutic termination of pregnancy, with 
surgical and/or medical techniques;
• complete or incomplete spontaneous abortion 
followed by dilation and curettage, regardless of 
the gestational age of the foetus;
• ectopic pregnancy90.
- In the first trimester (<12 weeks of gestation), even 
in the absence of traumatic manoeuvres to the uterus, 
the reported risk of alloimmunisation following 
abortion or blood loss is 1.5-2%. On this basis, some 
recommendations advise giving IP also following 
spontaneous abortion without dilation and curettage 
and for pharmacologically induced abortions85,89,91-98. 
 In these cases, a minimum dose of anti-D IgG is 
sufficient, i.e. from 250 to 600 IU (50-120 μg)21,83-84,88.
- In the event of copious blood loss, if the bleeding 
recurs in subsequent weeks, the anti-D Ig should 
be administered at intervals of 6 weeks99. After the 
 20th week the volume of FMH must be determined.
Table VIII - Recommendations on immunoprophylaxis 
following potentially immunising events during 
pregnancy. 
Rec. n. Recommendation GoR
20
In circumstances that can promote the passage of 
foetal red blood cells into the maternal circulation, 
it is suggested that prophylaxis with anti-D Ig is 
offered to all non-immunised RhD negative women.
2C
Systematic antenatal immunoprophylaxis (Table IX)
The aim of systematic antenatal IP is to protect 
against unpredictable, silent sensitisation which can 
occur in the third trimester of pregnancy, in order to 
prevent immunisation in subsequent pregnancies. 
In the absence of this type of IP, about 1% of RhD 
negative women who give birth to a RhD positive 
neonate could be sensitised87,95,96,100,101.
Various recommendations suggest systematic 
administration of antenatal IP to non-immunised RhD 
negative women1,21,70,75,83,86,88,91,102-105. Given that IP is effective 
for about 12 weeks, as indicated by pharmacokinetic 
studies on anti-D Ig97, and that the risk of significant FMH 
before 28 weeks is low, antenatal prophylaxis is advised 
from 28 weeks of gestation onwards106.
- It is recommended that all non-immunised RhD 
negative women are offered systematic antenatal IP 
with a dose of anti-D Ig of 1,500 IU (300 μg)98-106. In 
cases in which it is not possible to administer IP at 28 
weeks for organisational/logistic reasons, it can be give 
a few days earlier or later (27-29 weeks of gestation).
- Systematic antenatal IP should be performed even if 
IP has been given in the preceding weeks because of 
events that could cause immunisation.
- In the same way, sensitising events occurring after the 
administration of systematic antenatal IP should be 
managed with an additional dose of anti-D IgG and 
an evaluation of the FMH.
Table IX - Recommendations on systematic antenal 
immunoprophylaxis.
Rec. n. Recommendation GoR
21
It is recommended that all non-immunised RhD 
negative women are offered IP at 28 weeks of 
gestation with a dose of anti-D Ig of 1,500 IU 
(300 μg). IP at 28 weeks of gestation should be 
proposed even if IP was given in the preceding weeks 
because of a potentially immunising event.
1B
Post-partum immunoprophylaxis (Table X)
- All non-immunised RhD negative women 
who have delivered a RhD positive (or weak 
D) neonate (or stillborn baby) must be given 
a dose of anti-D Ig within 72 hours of the 
 delivery8,10,11,15,21,27,36,42,70-76,83,86-90,94,104-107.
- Anti-D Ig should also be given in cases in which the 
neonate's RhD group is not available. 
Table X - R e c o m m e n d a t i o n s  o n  p o s t - p a r t u m 
immunoprophylaxis.
Rec. n. Recommendation GoR
22
It is recommended that all non-immunised women 
who have given birth to a RhD positive (or weak D) 
neonate are given immunoprophylaxis with anti-D Ig.
1A
Times and methods of administering anti-D 
immunoglobulin (Table XI)
- Anti-D Ig must be given as soon as possible after the 
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delivery or potentially sensitising event, and at the 
latest within 72 hours. If IP is not performed within 
72 hours, an attempt to avoid immunisation must be 
made in any case with the administration of anti-D Ig up 
to 10 days after the event108. According to some authors, 
IP can still be attempted even with a delay of as much as 
28 days after the sensitising event36.
- The route of administration of choice for anti-D Ig is 
intramuscular. The deltoid muscle is an appropriate and 
safe site to maximise absorption70, but the gluteal region 
can also be used, taking particular care to ensure that the 
injection is made into muscle, since absorption can be 
delayed if the injection only reaches subcutaneous tissue.
- In the event of disorders of haemostasis (for example, 
severe thrombocytopenia or other bleeding diatheses), 
when intramuscular injections are contraindicated, it 
is recommended that the anti-D Ig are administered 
intravenously. It seems that both routes of administration 
are equally effective and that there are not significant 
differences between the two109. 
- It is suggested that anti-D Ig preparations for 
intramuscular administration are kept available for the 
cases set out in the previous section and the cases in 
which it is expected that high doses of anti-D Ig might 
have to be given because of massive FMH (see the last 
three points in the next paragraph). 
Table XI - Recommendations on times and methods of 
administering anti-D immunoglobulin.
Rec. n. Recommendation GoR
23
It is suggested that anti-D Ig is given as soon as 
possible after the delivery or potentially immunising 
event, and at latest within 72 hours. If the anti-D Ig is 
not given within 72 hours, it must be administered as 
soon as possible (up to 10 days afterwards).
2B
24
It is suggested that the anti-D Ig is given by 
intramuscular injection into the deltoid muscle. In 
the event of altered haemostasis, when intramuscular 
injections are contraindicated, or for doses greater 
than 3,000 IU (600 μg) it is suggested that the anti-D 
Ig is administered intravenously.
2C
Dose of anti-D immunoglobulin (Table XII)
The doses of anti-D reported in these recommendations 
are the minimum indicated for the specific situations 
mentioned. The dose of anti-D Ig should be commensurate 
with the amount of FMH. In the large majority of cases, 
a dose of 625 IU (125 μg) is considered sufficient to 
prevent active immunisation when the FMH does not 
exceed 4 mL of foetal red blood cells (99% of FMH).
- For prophylaxis following potentially immunising 
events occurring up to 19+6 weeks of gestation, 
a dose of 625 IU (125 μg) of Ig* is considered 
sufficient21,86-87,101.
- For all potentially immunising events occurring after 
20+0 weeks of gestation and after the delivery of a RhD 
positive neonate, a minimum dose of 625 IU (125 μg) of 
anti-D Ig should be administered, followed by evaluation 
of the FMH.
- If quantification of FMH shows that the volume 
of bleeding exceeded that covered by the dose 
administered, a further dose of anti-D Ig (125 IU every 
millilitre of RhD positive foetal red blood cells) must be 
injected110. The supplemental doses of anti-D Ig (rounded 
to the nearest dose of available packages) must take into 
account the dose of anti-D already administered.
- If the volume of FMH is not evaluated, for events 
occurring after week 20+0 of pregnancy and in the 
 post-partum period, a dose of 1,500 IU (300 μg) of anti-D 
Ig should be adminstered.
- In the event of a Caesarean section, twin birth or 
dystocia, the dose of anti-D Ig should always be 
 1,500 IU (300 μg).
- If the total dose of anti-D Ig to administer is greater than 
the contents of two intramuscular injections of 1,500 IU 
(bleeding >24 mL of foetal red blood cells) it is advisable 
to give the Ig intravenously.
- The total dose administered within a 24-hour period 
must not exceed 10,000 IU (2,000 μg).
- The maximum individual dose to be given 
intravenously must not exceed  4,500 IU (900 μg); 
 any additional doses must be administered at intervals 
of 12 hours. This indication is based on the known 
risk of haemolysis associated with the dose of anti-D 
Ig given intravenously in regimens used in RhD 
positive idiopathic thrombocytopenic purpura94.
Table XII - Recommendat ions  on dose of  ant i -D 
immunoglobulin.
Rec. n. Recommendation GoR
25
It is suggested that prophylaxis following sensitising 
events occurring up to 19
 
weeks of gestation consists of 
the administration of a dose of 625 IU (125 μg) anti-D Ig.
2B
26
For events occurring after 20+0 weeks of gestation 
and in the post-partum period, if the FMH is not 
quantified, it is suggested that the dose of anti-D Ig 
used is 1,500 IU (300 μg).
2B
27
If the amount of FMH is evaluated routinely, for 
events occurring after 20+0 weeks of gestation and in 
the post-partum period, it is suggested that the dose 
of anti-D Ig used is 625 IU (125 μg).
2B
28
If the FMH is greater than that covered by the dose 
of anti-D Ig given, it is suggested that the woman 
is administered supplementary doses of anti-D Ig 
commensurate with the volume of the FMH.
2B
* In Italy the only Ig available at a dose of 625 IU (125 μg) (RHESONATIV®, 
Octapharma Italy S.p.A., Pisa, Italy) carries the indication to use this 
dose up to the first trimester of pregnancy, whereas most Guidelines and 
Recommendations21,75,86-87 propose its use until the 20th week of gestation.
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Anti-D immunoglobulin preparations available 
in Italy
Anti-D Ig are blood derivatives obtained from the 
plasma of RhD negative donors with high levels of 
circulating anti-D, after voluntary immunisation.
There are various anti-D Ig preparations 
commercially available. Some are used exclusively by 
the intramuscular or subcutaneous route, while others 
can also be administered intravenously. The following 
preparations are currently available in Italy111:
- IGAMAD® (Grifols Italia S.p.A., Ghezzano-Pisa, 
Italy): available at the dose of 300 μg (1,500 
IU) in type 1 glass syringes for intramuscular or 
subcutaneous use (MA number 033867021).
- IMMUNORHO® (Kedrion S.p.A., Lucca. Italy): 
available at the dose of 200 μg (1,000 IU), in a vial, 
and at the dose of 300 μg (1,500 IU), in a vial or a 
pre-filled syringe for intramuscular or subcutaneous 
use (MA number 022547018).
- PARTOBULIN® (Baxter Ag, Vienna, Austria): 
available at the dose of 250 μg (1,250 IU) in a 
 pre-filled syringe, exclusively for intramuscular use 
(MA number 021974035).
- RHESONATIV® (Octapharma Italy S.p.A., Pisa, 
Italy): available at the dose of 125 μg (625 IU), in a vial 
for intramuscular or subcutaneous use (MA number 
039596010) and at the dose of 250 μg (1,250 IU), in 
an ampoule for intramuscular or subcutaneous use 
 (MA number 039596022).
- RHOPHYLAC® (CSL Behring GmbH, Marburg, 
Germany): available at the dose of 200 μg 
 (1,000 IU) or 300 μg (1,500 IU) in a pre-filled 
syringe, for intramuscular or intravenous use (MA 
number 036161026).
Evaluation of foetal-maternal haemorrhage
In 99% of pregnancies the amount of bleeding at 
birth is less than 4 mL of red blood cells. Various studies 
have, however, shown that about 0.3% of pregnancies 
are associated with a FMH greater than 15 mL at 
birth, an amount not covered by the maximum dose of 
1,500 IU (300 μg) of anti-D Ig112-114; furthermore, large 
volumes of FMH (>15 mL foetal red blood cells) can 
also occur during normal childbirth115. This means 
that as many as three out of every 1,000 RhD negative 
women could be at risk of alloimmunisation.
Clinical practice and the recommendations 
on IP differ between North America, Australia, 
the United Kingdom and continental Europe116. 
In countries such as the United Kingdom and 
Australia, in which the recommended, standard 
pos t -na ta l  dose  of  an t i -D i s ,  respec t ive ly, 
500 IU (100 μg) and 625 IU (125 μg), the test 
for evaluating FMH is recommended routinely, 
whereas  in  I ta ly  and many other  European 
countries, in which the dose of anti-D Ig used 
for postnatal  prophylaxis is  1,250-1,500 IU 
(250-300 μg), tests to evaluate FMH are not always 
used2,117. The AABB Standards require that a test is 
adopted that is able to determine the volume of an 
FMH so that further doses of Ig can be given if the 
FMH was not covered by the dose of anti-D Ig already 
administered118.
Main tests used to evaluate the volume of 
foetal-maternal haemorrhage 
Various different laboratory techniques have been 
proposed for the determination of whether a FMH 
has occurred and, if so, its volume. The most widely 
used screening test is the acid elution test described 
by Kleihauer and colleagues119, but there are others, 
including the consumption of anti-D monoclonal 
antibodies using a gel agglutination technique120 or a 
rosette test121. Flow cytometry techniques122, unlike the 
screening tests, can give a measure of the volume of 
the bleeding.
Kleihauer's acid elution test consists in identifying 
the cells, by microscopy, which contain foetal 
haemoglobin (HbF) present in a sample of the pregnant 
woman's blood. In some circumstances, such as 
congenital conditions characterised by high levels of 
HbF in the mother's blood, the results may be falsely 
positive. The test is based on a subjective evaluation 
by the person carrying out the test and its precision is 
limited to small volumes of transplacental bleeding.
For all these reasons, the Kleihauer test is only 
indicated as a screening test and in the event of a FMH 
greater than 2.5 mL, the amount of bleeding must be 
re-evaluated with a more precise method, such as flow 
cytometry123. Flow cytometry exploits monoclonal 
antibodies against RhD positive cells or, alternatively, 
monoclonal antibodies against HbF and the isoenzyme 
carbonic anhydrase, which is expressed in the first 
months of life. In this way it is possible to distinguish 
foetal blood cells from adults ones containing HbF 
(because woman who have haemoglobinopathies, even 
if they are heterozygous carriers, may have HbF in their 
blood cells, giving rise to false positive results). This 
type of technology is not available in all hospitals and 
in these cases, the samples must be sent to external 
laboratories.
 
When to evaluate foetal-maternal haemorrhage 
(Table XIII)
- FMH must be evaluated in non-immunised RhD 
negative women after the birth of a RhD positive 
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8. Monitoring and evaluation indicators for the 
clinical audit
With the aim of controlling some aspects of the 
management of the prevention of HDFN due to anti-RhD 
it is suggested that the following monitoring indicators 
are adopted:
- percentage of non-immunised RhD negative women 
who receive anti-D Ig after a sensitising event;
- percentage of non-immunised RhD negative women 
who receive antenatal prophylaxis at 28 weeks of 
gestation;
- percentage of non-immunised RhD negative women 
who receive anti-D Ig within 72 hours after the 
delivery of a RhD positive neonate;
- percentage of non-immunised RhD negative women 
who receive anti-D Ig more than 72 hours after the 
delivery of a RhD positive neonate;
- percentage of tests to evaluate FMH performed 
because of sensitising events after 20 weeks of 
gestation;
- percentage of tests to evaluate FMH performed after 
the delivery of a RhD positive neonate;
- percentage of immunised RhD negative women 
despite a complete programme of antenatal and 
postnatal prophylaxis;
- percentage of neonates who undergo ET for HDFN 
due to anti-D out of all neonates.
neonate or after potentially immunising events that 
occur after 20 weeks of gestation, particularly if a 
dose of 625 IU (125 μg) anti-D Ig is used.
- The evaluation of FMH is not advised in the event 
of potentially immunising events occurring before 
20 weeks of gestation124.
- A FMH must always be evaluated, independently of 
the dose of anti-D Ig administered, in cases in which 
there are factors associated with large volumes of 
bleeding:
• abdominal trauma during the third trimester;
• unexplained hydrops foetalis;
• placental abruption;
• external cephalic version;
• multiple pregnancies;
• stillbirths and intrauterine deaths;
• instrumental delivery;
• Caesarean delivery;
• manual removal of the placenta.
- The sample of blood on which to evaluate the 
FMH should be taken at least 30 minutes after but 
no later than 2 hours after the birth or potentially 
immunising event, in order to allow the neonatal 
or foetal blood to spread through the maternal 
circulation125,126. The sample must, in all cases, be 
taken before the administration of the anti-D Ig.
- The sample must be stored at a temperature between 
2 °C and 10 °C for no more than 2 days, but in any 
case, the test must be performed as early as possible, 
to enable administration of further doses of anti-D 
Ig within 72 hours of delivery or the sensitising 
event.
- The laboratories that quantify FMH must 
demonstrate acceptable performance in internal 
and external quality audits, use validated methods 
and have staff training programmes to guarantee 
the precision and reproducibility of the results.
- The results of the evaluation of FMH should be 
reported in a form that enables easy calculation 
of any supplementary dose of anti-D Ig that it is 
necessary to give or indicate the total dose of anti-D 
Ig to administer.
- Following administration of a supplementary dose 
of anti-D Ig, the test evaluating FMH must be 
repeated to determine the actual clearance of RhD 
foetal red cells from the maternal circulation. This 
re-evaluation must be conducted 48-72 hours after 
the administration of the anti-D Ig.
Table XIII - Recommendations on when to evaluate 
foetal-maternal haemorrhage.
Rec. n. Recommendation GoR
29
With the aim of calculating the appropriate dose of 
anti-D Ig to administer, it is suggested that FMH 
is evaluated in RhD negative women after giving 
birth to a RhD positive neonate or after potentially 




Independently of the dose of anti-D Ig administered, 
it is suggested that FMH is evaluated in cases in 




It is suggested that the blood sample in which to 
evaluate FMH is taken at least 30 minutes afer but 
no later than 2 hours after the delivery or potentially 
immunising event in order to allow the foetal or 
neonatal blood to spread throughout the maternal 
circulation. In all cases, the sample must be taken 
before the anti-D Ig is given.
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